Researchers from Analysis Group, a global leader in health economics and outcomes research (HEOR), have co-developed a new framework that leverages findings from clinical trials and real-world ...

Shares of AbbVie Inc. ABBV rose 1.79% to $200.88 Thursday, on what proved to be an all-around poor trading session for the ...

The rise of remote work is transforming real estate, driving demand for flexible workspaces, data centers, and suburban ...

AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

Dividend-growth stocks offer steady income and long-term value. With the Fed holding rates and inflation expected to ease, ...

Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...

Full Year 2024 Results Key Financial Results Revenue: US$56.3b (up 3.7% from FY 2023). Net ...

Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell engagers, with $52.0 million in upfront payments Extended ant ...

Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell ...

Highlights,Wilmington Savings Fund Society FSB increased its stake in AbbVie Inc. (NYSE:ABBV) by 8.5% during the fourth ...